Kaiser Permanente study assessed of Pfizer–BioNTech COVID-19First identified in 2019 in Wuhan, China, Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has spread globally, resulting in the 2019–20 coronavirus pandemic.” data-gt-translate-attributes=”[{“attribute”:”data-cmtooltip”, “format”:”html”}]”>COVID-19 vaccine effectiveness against infection, hospitalization, and death up to 8 months after vaccination.
A Kaiser Permanente study published today (February 14, 2022), in The LancetFounded in 1823 by Thomas Wakley, The Lancet is a weekly peer-reviewed general medical journal. It is one of the world's oldest, most prestigious, and best known general medical journals. The journal publishes original research articles, review articles ("seminars" and "reviews"), editorials, book reviews, correspondence, as well as news features and case reports. The Lancet has editorial offices in London, New York, and Beijing. ” data-gt-translate-attributes=”[{“attribute”:”data-cmtooltip”, “format”:”html”}]”>The Lancet Regional Health – Americas found that one month after a third dose, the Pfizer-BioNTech COVID-19 vaccine effectiveness is higher for preventing infection and hospitalization than 2 doses of the vaccine after 1 month.
“When we looked at the effectiveness of the 2 doses of Pfizer–BioNTech vaccine versus 3 doses, we see a benefit with 3 doses that exceeds that achieved with 2 doses alone,” said Sara Y. Tartof, PhD, an epidemiologist with the Kaiser Permanente Southern California Department of Research & Evaluation and a member of the faculty of the Kaiser Permanente Bernard J. Tyson School of Medicine, both in Pasadena.
This study assessed the primary series of two doses of the Pfizer-BioNTech COVID-19 vaccination effectiveness against infection, hospitalization, and death up to 8 months after vaccination, and also assessed the effectiveness of 3 doses of the vaccine up to 3 months after vaccination.
To assess effectiveness, this research study evaluated electronic health records of 3.1 million members of Kaiser Permanente in Southern California from December 14, 2020, to December 5, 2021. During the study period, 197,535 (6.3%) patients were infected with SARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the official name of the virus strain that causes coronavirus disease (COVID-19). Previous to this name being adopted, it was commonly referred to as the 2019 novel coronavirus (2019-nCoV), the Wuhan coronavirus, or the Wuhan virus.” data-gt-translate-attributes=”[{“attribute”:”data-cmtooltip”, “format”:”html”}]”>SARS-CoV-2, and of those, 15,786 (8%) were admitted to the hospital. During the study period, the predominant variant was delta, and not omicron.
- 2-dose vaccine effectiveness against infection declined from 85% during the first month after vaccination to 49% up to 8 months following vaccination.
- 2-dose vaccine effectiveness against hospitalization remained high (90%) throughout the 8 months and did not wane, except among people who were 75 years of age and older, or who had compromised immune systems.
- For people who were immunocompromised, the protection against hospitalization dropped to 74%, and for those 75 and older, it was 77%.
- 3-dose vaccine effectiveness was 88% against infection and 97% against hospitalization within the first 3 months after vaccination.
“What we see from this research is that the public health impact of a third dose to prevent severe disease is substantial,” Tartof said. “Importantly, all studies that have evaluated the vaccine effectiveness of a third dose — including ours — have shown a meaningful improvement in vaccine effectiveness against a broad range of SARS-CoV-2 outcomes.”
Reference: “Effectiveness of a Third Dose of BNT162b2 mRNA COVID-19 Vaccine in a Large US Health System: A Retrospective Cohort Study” by Tartof, Sara Y. and Slezak, Jeff M. and Puzniak, Laura and Hong, Vennis and Frankland, Timothy B. and Ackerson, Bradley K. and Takhar, Harpreet S. and Ogun, Oluwaseye A. and Simmons, Sarah and Zamparo, Joann M. and Gray, Sharon and Valluri, Srinivas R. and Pan, Kaijie and Jodar, Luis and McLaughlin, John M.,14 February 2022, The Lancet Regional Health – Americas.
DOI: 10.2139/ssrn.3989856
Source: SciTechDaily
